tbuckley/cabot-search huggingface dataset:
Handbook of Regional Anatomy.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alligator Bite
Authors: E. J. DOERING
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Alligator bites are rare. A successfully treated case and courageous bacteriologic studies are reported. Basic surgical principles and anti-clostridial chemoprophylaxis constitute the optimal care of patients ravaged by alligators. <h3>Report of a Case.—</h3> A 49-year-old farmer complained of having been bitten either by the devil or an alligator. From numerous versions of the event, the following facts are given credence. One hour before appearing in the emergency room, the farmer was returning home on foot from a prayer meeting in a rural island area, on a path which led through a swamp. Suddenly, to the accompaniment of hissing and scuffling on the muddy bank of the path, the patient felt his right thigh locked in the jaw of some large beast. The patient was able to extricate his leg from the apparent alligator by beating it about the head with the family Bible. Debridement, cleansing of the
Operational and financial outcomes of shared laboratory services in a consolidated hospital system
Authors: G. A. Fattal
Journal: JAMA (1985)

The clinical laboratories of three hospitals were consolidated under a single directorship. Improvements in available services and substantial true cost savings were achieved. These results illustrate the theoretically anticipated but rarely documented advantages of a shared-hospital services model of health care provision. (<i>JAMA</i>1985;253:2076-2079)
Length of survival with brain metastases
Authors: J. G. Mira
Journal: JAMA (1981)

<h3>In Reply.—</h3> The main point of Dr Mira's letter is that patients with small cell carcinoma of the lung have a greater tendency to have brain metastases develop with increasing length of survival. We agree with this statement and expressed this in our article. Our article states that the present aggressive regimens may result in an improved survival and, therefore, an increase in the incidence of brain metastases. This hypothesis was based on our finding that those patients who lived longer had an increased incidence of brain metastases. We then quoted Hansen who had similar findings and conclusions. Perhaps instead of stating that "patients who developed brain metastases had a longer survival," any misinterpretation could have been prevented if we had simply stated that those patients who survived longer had a greater tendency to have the development of brain metastases. We do agree with the comments by Dr Mira on
Evaluation of CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon
Authors: H. Gogas, Y. Metaxas, U. Dafni, A. Polyzos, G. Fountzilas, E. Pectasides, D. Skarlos, D. Tsoutsos, P. Panagiotou, M. Spyropoulou-Vlachou
Journal: Journal of Clinical Oncology (2008)

9054 Background: Attempts to identify patients who benefit from adjuvant treatment with interferon alfa-2b (IFN) have been disappointing. The development of autoimmunity during adjuvant therapy with IFN cannot assist selection of patients for therapy at baseline. Multiple polymorphisms within the CTLA-4 gene have been found to be associated with autoimmune diseases. We therefore evaluated six CTLA- 4 single nucleotide polymorphisms (SNPs) in high-risk melanoma patients enrolled in a study of two regimens of high-dose IFN and compared the distribution of SNPs found in healthy controls. Methods: We genotyped DNA from peripheral blood of 203 stage IIb, IIc and III melanoma patients and 288 healthy controls for 49 A/G, 60 C/T, 318 C/T, JO27, JO30 and JO31 using PCR and pyrosequencing technology (Biotage, Uppsala, Sweden). Results: At a median follow up of 57.3 months (95% CI 50.14–64.76), 115 patients have recurred and 58 have died. The median DFS was 42 months and the median OS has not been reached yet (mean OS: 65 months). There were no statistical significant differences in the incidence of CTLA-4 polymorphisms between melanoma patients and healthy controls. The tabular distribution of these polymorphisms in melanoma patients is presented below. RFS and OS did not differ significantly between patients with the alleles represented by these polymorphisms (p=0.90 and p=0.28 for 49 A/G, p=0.89 and p=0.9 for 60 C/T, p=0.63 and p=0.72 for 318 C/T, p=0.88 and p=0.69 for JO27, p=0.74 and p=0.97 for JO30, p=0.6 and p=0.92 for JO31 respectively). High association between the different polymorphisms was found (Fishers´ exact p-values <.001 for all associations). Conclusions: No polymorphism of CTLA4 defined by the SNPs studied was correlated with improved RFS or OS in this high-risk group of melanoma patients. 49A/G (%) 60 C/T (%) 318 CT (%) JO27 (%) JO30 (%) JO31 (%) A/A 46.3 A/G 53.2 C/C 79.8 T/C 53.7 G/A 51.7 G/T 52.7 A/G 43.3 A/A 22.2 C/T 19.2 C/C 23.6 A/A 24.1 T/T 23.2 G/G 10.3 G/G 24.6 T/T 1 T/T 22.7 G/G 24.1 G/G 24.1 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Schering-Plough
A "New" Antigen in Leukemia Sera
Authors: Baruch S. Blumberg
Journal: JAMA (1984)

Patients who receive large numbers of transfusions for anemia and other causes may develop precipitins in their blood. These precipitins may react in agar gel double diffusion experiments with specific human serum lipoprotein found in the blood of other individuals. Since these precipitins were found only in patients who had received transfusions they were thought to be antibodies against serum lipoproteins which developed in the patients as a result of the repeated transfusions. The precipitin is referred to as an isoprecipitin since it develops against a specificity found in an individual from the same species. The antilipoprotein isoprecipitin<sup>1,2</sup>developed in approximately 30% of 47 patients with thalassemia who had received transfusions. Isoprecipitins also developed in a smaller number of transfused patients with other diseases. All precipitins stained with sudan black, a dye specific for lipid. Immunoelectrophoretic and ultracentrifugal studies showed that the protein with which the isoprecipitins reacted was
The relation of androgen receptors status, neuroendocrine differentiation and angiogenesis to biochemical failure after radical prostatectomy for localized prostate cancer
Authors: K. Revelos, C. D. Petraki, M. M. Vaslamatzis, P. Papanastassiou, C. Mastoris, C. Magkou, T. Argyrakos, N. Alevizopoulos, E. Vrionis, M. Koutsilieris
Journal: Journal of Clinical Oncology (2004)

4691
Nanotechnology Hazard?
Authors: Joan Stephenson
Journal: JAMA (2008)

Some carbon “nanotubes”—a key nanotechnology product—may behave like asbestos fibers and pose a health threat, according to new research in mice (Poland CA et al. Nat Nanotechnology. 10.1038/nnano.2008.111 [published online ahead of print May 20, 2008]).
AUSTRALIA
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Echocardiography
Authors: Richard L. Popp
Journal: New England Journal of Medicine (1990)

Pericardial DiseaseEchocardiography is the procedure of choice for the diagnosis of pericardial effusion. The method is extremely sensitive in the detection of even small effusions, and the amount of fluid can be estimated by considering the size of the heart and the distance between the epicardium and the parietal pericardium.71 Categories of less than 100 ml, 100 to 500 ml, and larger than 500 ml may be used with reasonable accuracy. The use of echocardiography to direct pericardiocentesis has been shown to increase the number of cases in which fluid can be obtained and to decrease the complication rate . . .
Nature, London
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NCCN News
Authors: Ms Pausch, Randy Pausch
Journal: Journal of the National Comprehensive Cancer Network (2011)

The Last Lecture, responds to a reader's question about feeling as though "time is slipping away" in this month's column.Ms. Pausch reminds the reader that battling cancer "is a marathon, not a sprint" -a mantra that should be kept in mind when prioritizing time and energy.In addition, she emphasizes the need to address caregiver anxieties through support groups and the importance of nutrition and exercise to strengthen both the caregiver and patient as they prepare for treatment.Visit NCCN.com to read the column in its entirety."Ask Jai" is a monthly column on NCCN.com, the patient Web site of NCCN.NCCN.com features the NCCN Guidelines for Patients as well as enhanced content for patients and caregivers. Active Surveillance Monitoring More Stringent in Updated NCCN Guidelines for Prostate CancerActive surveillance or immediate treatment?The question that many men with prostate cancer and their clinicians struggle with continues to be a focus in the updated NCCN Guidelines for Prostate Cancer.James L. Mohler, MD, of Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, discussed more rigorous monitoring of men undergoing active surveillance and new treatment options for advanced prostate cancer in the recently updated NCCN Guidelines during a presentation at the NCCN 16th Annual Conference.
The Etiology of Yellow Fever
Authors: Walter Reed
Journal: JAMA (1983)

At the Twenty-eighth Annual Meeting of the American Public Health Association,<sup>1</sup>held in Indianapolis, Ind., Oct. 22-26, 1900, we presented, in the form of a preliminary note, the results of our bacteriologic study of yellow fever, based on cultures taken from the blood in eighteen cases, at various stages of the disease, as well as on those which we had made from the blood and organs of eleven yellow fever cadavers. We also recorded the results obtained from the inoculation of eleven non-immune individuals by means of the bite of mosquitoes (culex fasciatus, Fabr.) that had previously fed on the blood of patients sick with yellow fever. We were able to report two positive results, in which the attack of yellow fever followed the bite of a mosquito within the usual period of incubation of this disease. In one of these cases all other sources of infection could be positively
From the NIH: Primate studies indicate that subclinical and acute vitamin C deficiency may lead to periodontal disease
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Available
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants
Journal: Clinical Cancer Research (2010)

issue of Clinical Cancer Research (1), there was an error in the second paragraph of the Results section.It currently reads, "Median time to death was 2.8 years (range, 0.9-11.8years) for the intervention arm and 2.2 years (range, 0.2-12.0years) for the assessment arm."These data were correctly reported previously as the median time to recurrence (2).The sentence should read, "Median time to death was 3.2 years (range, 0-6.6 years) for the intervention arm and 1.7 years (range, 0.2-4.2years) for the assessment arm."These data suggest a doubling of time to the endpoint.The authors regret any confusion.
Selectins.
Authors: M P Bevilacqua, R M Nelson
Journal: Journal of Clinical Investigation (1993)

EGF, epidermal growth factor; PPME, phosphomannan monoester core polysaccharide; sLea, sialyl Lewis a; sLeX, sialyl Lewis x; TNF, tumor necrosis factor.ble I).In this Perspectives article, we discuss the selectins and their carbohydrate ligands: what they are, where they are found, and why they are important.We attempt to present the major discoveries and developments in sufficient detail for clarity, and to provide insights that may be ofhelp in managing the abundant information in this area.We apologize for any oversights that we have made.Other recent reviews may also be of interest (19)(20)(21)(22)(23)(24).
CLINICAL OBSERVATIONS ON THE DIGITALIS-LIKE ACTION OF SQUILL
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Procarbazine in the management of late Hodgkin's disease
Authors: R. C. DeConti
Journal: JAMA (1971)

Thirteen of 22 patients with widespread Hodgkin's disease resistant to vinca alkaloids and alkylating agents responded to therapy with procarbazine hydrochloride. All responses were clinically evident three weeks after therapy was begun. Four complete and nine partial remissions were achieved ranging from 4 to more than 40 weeks in duration with a median duration of 10 weeks. The relatively short duration of response and the paucity of complete remissions in these patients may be related to the severity of the disease. Procarbazine hydrochloride has been demonstrated to be a safe, effective agent in the drug management of advanced Hodgkin's disease.
Dietary Supplements
Authors: Daniel Kesden
Journal: JAMA (1987)

<h3>To the Editor.—</h3> In the April 10, 1987, issue of<i>JAMA</i>, there was an article entitled "Vitamin Preparations as Dietary Supplements and as Therapeutic Agents" by the Council on Scientific Affairs of the American Medical Association.<sup>1</sup>There is a statement in this article to the effect that there is no evidence that taking supplemental carotene will prevent cancer in man. This statement is incorrect; indeed, there are other benefits from a high intake of beta carotene. First, there is epidemiologic evidence that low levels of beta carotene increase the risk of several types of cancer. The intake of dietary beta carotene was inversely related to the development of cancer of the lung in the Western Electric study<sup>2</sup>and several other studies.<sup>3,4</sup>Beta carotene may be protective against oral, gastrointestinal, and cervical cancer as well. Currently, several studies in progress are testing the effects of supplemental beta carotene
Journal Irish Medical Association, Dublin
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OA07.01 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)
Authors: J. Bauml, R. Mick, C. Ciunci, C. Aggarwal, C. Davis, T. Evans, C. Deshpande, L. Miller, P. Patel, E. Alley, C. Knepley, F. Mutale, R. Cohen, C. Langer
Journal: Journal of Thoracic Oncology (2018)